BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34627860)

  • 21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
    Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
    Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
    Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
    Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
    Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
    Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.
    Le Y; Gao H; Richards W; Zhao L; Bleday R; Clancy T; Zhu Z
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical activity of cobimetinib alone or in combination with chemotherapy and targeted therapies in renal cell carcinoma.
    Zhang L; Xie D; Lei Y; Na A; Zhu L
    Future Oncol; 2021 Aug; 17(23):3051-3060. PubMed ID: 33906367
    [No Abstract]   [Full Text] [Related]  

  • 27. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.
    Cheung PF; Yang J; Fang R; Borgers A; Krengel K; Stoffel A; Althoff K; Yip CW; Siu EHL; Ng LWC; Lang KS; Cham LB; Engel DR; Soun C; Cima I; Scheffler B; Striefler JK; Sinn M; Bahra M; Pelzer U; Oettle H; Markus P; Smeets EMM; Aarntzen EHJG; Savvatakis K; Liffers ST; Lueong SS; Neander C; Bazarna A; Zhang X; Paschen A; Crawford HC; Chan AWH; Cheung ST; Siveke JT
    Nat Commun; 2022 Jan; 13(1):156. PubMed ID: 35013174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
    Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM
    Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
    Hundeyin M; Kurz E; Mishra A; Rossi JAK; Liudahl SM; Leis KR; Mehrotra H; Kim M; Torres LE; Ogunsakin A; Link J; Sears RC; Sivagnanam S; Goecks J; Islam KMS; Dolgalev I; Savadkar S; Wang W; Aykut B; Leinwand J; Diskin B; Adam S; Israr M; Gelas M; Lish J; Chin K; Farooq MS; Wadowski B; Wu J; Shah S; Adeegbe DO; Pushalkar S; Vasudevaraja V; Saxena D; Wong KK; Coussens LM; Miller G
    Cancer Discov; 2019 Sep; 9(9):1288-1305. PubMed ID: 31266770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
    Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
    Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
    Byrne KT; Vonderheide RH
    Cell Rep; 2016 Jun; 15(12):2719-32. PubMed ID: 27292635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
    Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
    J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of miR-340 controls pancreatic cancer cell
    Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
    Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
    Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
    Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.
    Seifert L; Werba G; Tiwari S; Giao Ly NN; Nguy S; Alothman S; Alqunaibit D; Avanzi A; Daley D; Barilla R; Tippens D; Torres-Hernandez A; Hundeyin M; Mani VR; Hajdu C; Pellicciotta I; Oh P; Du K; Miller G
    Gastroenterology; 2016 Jun; 150(7):1659-1672.e5. PubMed ID: 26946344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.